BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794 [PMID: 30533179 DOI: 10.4254/wjh.v10.i11.790]
URL: https://www.wjgnet.com/1948-5182/full/v10/i11/790.htm
Number Citing Articles
1
Maria-Styliani Kalogirou, Dimitrios Patoulias, Anna-Bettina Haidich, Evangelos Akriviadis, Emmanouil Sinakos. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trialsClinics and Research in Hepatology and Gastroenterology 2021; 45(3): 101568 doi: 10.1016/j.clinre.2020.10.012
2
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategiesPharmacological Research 2020; 159: 104984 doi: 10.1016/j.phrs.2020.104984
3
Hae Jin Kim. Recent Updates on Glucagon-Like Peptide 1 Receptor AgonistThe Journal of Korean Diabetes 2021; 22(2): 126 doi: 10.4093/jkd.2021.22.2.126
4
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!Metabolism 2019; 101: 154001 doi: 10.1016/j.metabol.2019.154001
5
Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Seisuke Sato, Toshihiro Kobayashi, Tao Dong, Takanobu Saheki, Mari Matsumoto, Hisakazu Iwama, Huanxiang Zhang, Koji Murao. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytesMolecular Metabolism 2020; 34: 16 doi: 10.1016/j.molmet.2019.12.015
6
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-AnalysisFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.609110
7
E. S. Shcherbakova, T. S. Sall, S. I. Sitkin, T. Ya. Vakhitov, E. V. Demyanova. The role of bacterial metabolites derived from aromatic amino acids in non-alcoholic fatty liver diseaseAlmanac of Clinical Medicine 2020; 48(6): 375 doi: 10.18786/2072-0505-2020-48-066
8
Maja Cigrovski Berkovic, Lucija Virovic-Jukic, Ines Bilic-Curcic, Anna Mrzljak. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and managementWorld Journal of Gastroenterology 2020; 26(21): 2740-2757 doi: 10.3748/wjg.v26.i21.2740
9
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosisExpert Opinion on Pharmacotherapy 2020; 21(13): 1637 doi: 10.1080/14656566.2020.1774553
10
Yunzhi Chen, Xuemei Yan, Xiao Xu, Shuhua Yuan, Fen Xu, Hua Liang. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatideEndocrine 2020; 70(3): 517 doi: 10.1007/s12020-020-02470-7